Regeneron’s Eylea wins FDA approval
The drug is the only VEGF inhibitor approved with two dosing options for diabetic retinopathy.
Read More
Tag: diabetic retinopathy
Roche’s bags new US approvals for Tecentriq, Lucentis
The US Food and Drug Administration has expanded the approval of Roche’s Tecentriq so that it can be used to treat a wider range of patients with bladder cancer.
Read More
Thousands take part in diabetic retinopathy screening trial
More than 4,500 people from Liverpool with diabetes are taking part in a new a clinical trial designed to help transform early detection of diabetic eye disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
